Consensus Ovid Therapeutics Inc.

Stocks

OVID

US6904691010

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 04/09/2026 BST			5-day change	1st Jan Change
2.800 ^USD	+0.72%		-4.44%	+71.78%

08-13	Ovid Therapeutics Reports Pipeline and Business Updates	CI
08-13	Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Ovid Therapeutics Inc.

Evolution of the Target Price: Ovid Therapeutics Inc.

Changes in Analyst Recommendations: Ovid Therapeutics Inc.

d1236e3032fa60db220e5.VIXx_lTCeh-m_0cIjrQcTAPjM_xpZj8wJHnXVvmtYsQ.HOi2qhKvFG3kt38_-9MlJGvWALc5P35qXRuOOsvbEfAVt5iIFpUJbJG3Hg~26c2e95ac384f6533d60d543f08ff775

Analysts' recommendations: Ovid Therapeutics Inc.

08-03	Oppenheimer Adjusts Ovid Therapeutics Price Target to $9 From $7, Maintains Outperform Rating	MT
03-19	Wedbush Raises Price Target on Ovid Therapeutics to $7 From $5, Keeps Outperform Rating	MT
12-11	Roth Capital Initiates Ovid Therapeutics With Buy Rating, $3 Price Target	MT
11-17	Leerink Partners Initiates Ovid Therapeutics at Outperform With $5 Price Target	MT
11-12	Ovid Therapeutics Q3 revenue slightly beats expectations	RE
09/10/25	Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says	MT
06/10/25	Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating	MT
03/10/25	Wedbush Adjusts Ovid Therapeutics Price Target to $5 From $3, Maintains Outperform Rating	MT
03/10/25	Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million	MT
12/03/25	Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating	MT
29/01/25	Oppenheimer Upgrades Ovid Therapeutics to Outperform From Perform, $4 Price Target	MT
18/06/24	Oppenheimer Downgrades Ovid Therapeutics to Market Perform	MT
18/06/24	B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating	MT
18/06/24	BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating	MT
18/06/24	HC Wainwright Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating	MT
18/06/24	Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating	MT
17/06/24	Top Midday Decliners	MT
17/06/24	Wedbush Lowers PT on Ovid Therapeutics to $4 From $8 After Soticlestat Missed Endpoints in Phase 3 Studies; Maintains Outperform Rating	MT
30/04/24	B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target	MT
29/04/24	HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target	MT
21/12/23	BTIG Initiates Ovid Therapeutics With Buy Rating, Price Target is $11	MT
13/10/23	Oppenheimer Initiates Coverage on Ovid Therapeutics With Outperform Rating, $8 Price Target	MT
14/06/23	JonesTrading Initiates Ovid Therapeutics at Buy With $6 Price Target	MT
20/05/22	Citigroup Adjusts Ovid Therapeutics' Price Target to $2.40 from $4, Keeps Neutral Rating	MT
25/08/21	Ovid Therapeutics : Citigroup Adjusts Ovid Therapeutics' Price Target to $4 from $4.50, Keeps Neutral Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OVID THERAPEUTICS INC.					+108.79%
	WUXI APPTEC CO., LTD.					+18.92%
	ARGENX SE					+9.64%
	INSMED INCORPORATED					+58.02%
	BIONTECH SE					+16.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+13.1%
	GENMAB A/S					+10.47%
	PHARMAESSENTIA CORPORATION					+3.5%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+24.48%
	EXELIXIS, INC.					-9.2%
	Average					+25.47%
	Weighted average by Cap.					+17.29%